Lactobacillus reuteri

Phase 2Biologic

TTulane University School of Medicine

Lactobacillus reuteri is one of 21 biologic programs targeting Chronic Periodontitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PeriodontitisActive, not recruiting

Androgenetic AlopeciaNot yet recruiting

Chronic PeriodontitisPreclinical

Active, not recruiting

Androgenetic AlopeciaPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in Chronic Periodontitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

1 2

Zocor

OOrganon and Co

Approved

2 3

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

2 4

Fosamax

OOrganon and Co

Approved

1 5

Glucophage

EMD Serono

Approved

1 6

Singulair

OOrganon and Co

Approved

1 7

Minocin

TTriax

Approved

1 8

Lactobacillus reuteri

TTulane University School of Medicine

Phase 2

2 9

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

—10

Flagyl

PPar Pharmaceutical, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Androgenetic Alopecia

NCT07370519

Clinical

Trials by Indication[1]

Oral Mucositis2 trials

Effects of Probiotics in Preventing Oral Mucositis

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT03552458·50 enrolled

Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

Completed·WWest China Hospital·Phase 2·NCT06285591·160 enrolled

Chronic Periodontitis2 trials

Antibiotic and Probiotic Therapies in the Adjuvant Treatment of the Chronic Periodontitis.

Completed·UUniversidade Estadual Paulista Júlio de Mesquita Filho·N/A·NCT03692819·45 enrolled

The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis

Completed·TTanta University·Phase 1·NCT04697199·12 enrolled

Children2 trials

Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months

Completed·TTulane University School of Medicine·Phase 1·NCT02460575·60 enrolled

Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru

Completed·TTulane University School of Medicine·Phase 1·NCT02124122·60 enrolled

Androgenetic Alopecia1 trial

Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia

Not yet recruiting·SShenzhen People's Hospital·Phase 2·NCT07370519·388 enrolled

Chronic constipation1 trial

Lactobacillus Reuteri in Adult With Functional Chronic Constipation

Completed·—·Phase 3·NCT01870700·40 enrolled

3 more indications

Completed·TTulane University School of Medicine·Phase 1·NCT00774163·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lactobacillus reuteri. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus reuteri compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus reuteri. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tulane University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TTulane University School of Medicine

Lactobacillus reuteri

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Oral Mucositis2 trials

Chronic Periodontitis2 trials

Children2 trials

Androgenetic Alopecia1 trial

Chronic constipation1 trial

Necrotizing Enterocolitis1 trial

Inflammation1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News